GE HealthCare Technologies Inc.
NasdaqGS:GEHC Stok Raporu
GE HealthCare Technologies Gelecekteki Büyüme
Future kriter kontrolleri 1/6 GE HealthCare Technologies kazanç ve gelirin sırasıyla yıllık 11.6% ve 4.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 12.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 17.4% olacağı tahmin edilmektedir.
Anahtar bilgiler Medical Equipment kazanç büyümesi 17.3% Gelir büyüme oranı 4.4% Gelecekteki özkaynak getirisi 17.4% Analist kapsamı Good
Son güncelleme 09 Nov 2024
Gelecekteki son büyüme güncellemeleri
GE HealthCare Technologies Inc. Updates Earnings Guidance for the Full Year 2024 Nov 02
GE Healthcare Technologies Inc. Updates Earnings Guidance for the Year 2024 Aug 01
GE Healthcare Technologies Inc. Updates Earnings Guidance for the Year 2024 Jul 31 GE HealthCare Technologies Inc. Reaffirms Earnings Guidance for the Full Year 2024
Tüm güncellemeleri göster GE HealthCare Technologies Inc. has completed a Follow-on Equity Offering. GE HealthCare Technologies Inc. has filed a Follow-on Equity Offering. Nov 08
GE HealthCare Technologies Inc. Updates Earnings Guidance for the Full Year 2024 Nov 02
Third quarter 2024 earnings: EPS exceeds analyst expectations Nov 01
From Spin-Off To Standout: GE HealthCare Is Pretty Impressive Oct 30
GE HealthCare Technologies Inc. Announces Hospital Pulse, the Newest Tile for Its Command Center Software Platform Oct 18
GE HealthCare Introduces Easy-To-Use, Easy-To-Learn, Easy-To-Appoint Versana Premier Multi-Purpose Ultrasound System Oct 14
Upcoming dividend of US$0.03 per share Oct 11
GE Healthcare Accelerates Artificial Intelligence Adoption with New Offering to Advance Enterprise Imaging Oct 10
GE HealthCare Technologies Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 08
GE HealthCare Announces Phase I Results for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent Oct 07
GE Healthcare Announces FDA Approval of Flyrcado (Flurpiridaz F 18) Injection Pet Radiotracer for Enhanced Diagnosis of Coronary Artery Disease Sep 30
Second quarter dividend of US$0.03 announced Sep 23 GE HealthCare Introduces Elevated Venue Point of Care Ultrasound Solutions and New Tablet-Based Venue Sprint
GE HealthCare: The Image Of More Upside Is Very Real Sep 18 GE HealthCare Technologies Inc. has filed a Follow-on Equity Offering.
Are Investors Undervaluing GE HealthCare Technologies Inc. (NASDAQ:GEHC) By 28%? Sep 05
GE HealthCare Technologies Inc. Showcases Latest AI-Enhanced Cardiology Solutions to Enable Real-Time Cardiac Imaging and Assessments At the Point of Care At ESC 2024 Aug 26
GE HealthCare Announces the Publication of the MASTER Trial Results in the Peer-Reviewed Journal Anesthesia and Analgesia Aug 21
Insider recently sold US$1.6m worth of stock Aug 18
GE HealthCare Q2 Earnings Recap (Rating Downgrade) Aug 06
Second quarter 2024 earnings: EPS exceeds analyst expectations Aug 01
GE Healthcare Technologies Inc. Updates Earnings Guidance for the Year 2024 Aug 01
GE Healthcare Technologies Inc. Updates Earnings Guidance for the Year 2024 Jul 31
Upcoming dividend of US$0.03 per share Jul 15
GE HealthCare Technologies Inc. to Report Q2, 2024 Results on Jul 31, 2024 Jul 09
GE HealthCare: Near-Term Risks, But Some Interesting Longer-Term Opportunities Jul 07
First quarter dividend of US$0.03 announced Jul 01
GE HealthCare Technologies Inc. Announces Cash Dividend for Second Quarter of 2024, Payable on August 15, 2024 Jun 26
GE Healthcare Names Adam Holton as Chief People Officer Jun 01
Is GE HealthCare Technologies (NASDAQ:GEHC) A Risky Investment? May 21
President & CEO of Imaging notifies of intention to sell stock May 15
GE HealthCare Unveils SIGNA MAGNUS, an FDA 510(K) Pending Head-Only Magnetic Resonance (MR) Scanner Designed to Explore Advance Advancements in Neuro Science May 06
GE HealthCare: Too Soon To Buy After A Mixed Q1 (Rating Downgrade) May 02
GE HealthCare Launches New Era of AI-Enhanced, Personalized Oncology Solutions at ESTRO 2024 Congress May 02
First quarter 2024 earnings: EPS and revenues miss analyst expectations May 01 GE HealthCare Technologies Inc. Reaffirms Earnings Guidance for the Full Year 2024
GE HealthCare Technologies Inc.'s (NASDAQ:GEHC) Intrinsic Value Is Potentially 100% Above Its Share Price Apr 25
GE HealthCare Introduces AI-Enhanced Voluson Signature 20 and 18 Ultrasound Systems to Advance Women's Health Imaging Apr 19
Upcoming dividend of US$0.03 per share Apr 11
GE HealthCare Technologies Inc. to Report Q1, 2024 Results on Apr 30, 2024 Apr 10 GE HealthCare Technologies Inc., Annual General Meeting, May 21, 2024 Apr 05
GE Healthcare Introduces Caption AI on Vscan Air SL Wireless Handheld Ultrasound System to Help More Clinicians Capture Diagnostic-Quality Cardiac Images Apr 03
GE Vernova: An Interesting Stalwart To Ride The Energy Transition Apr 02 GE HealthCare Unveils AI-Enabled Urology Software Feature Prostate Volume Assist
GE HealthCare Technologies: Growth Prospects Remain Encouraging, And Valuation Is Attractive Mar 25
GE HealthCare Technologies Inc. to Feature Latest Technologies in Interventional Radiology Focused on Precision Care At Sir 2024 Mar 22 GE HealthCare Technologies Inc. has filed a Follow-on Equity Offering. Mar 13
GE HealthCare Technologies' Roar Higher Isn't Over Yet Mar 09 GE HealthCare Technologies Inc. has completed a Follow-on Equity Offering in the amount of $1.06925 billion. Feb 17
GE HealthCare Technologies Inc. has filed a Follow-on Equity Offering.
GE HealthCare Technologies: Stable Business, But Future Upside Seems Limited Feb 14
Kazanç ve Gelir Büyüme Tahminleri NasdaqGS:GEHC - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions ) Tarih Gelir Kazançlar Serbest Nakit Akışı Faaliyetlerden Nakit Avg. Analist Sayısı 12/31/2026 21,616 2,313 2,409 2,884 16 12/31/2025 20,572 2,053 2,231 2,524 19 12/31/2024 19,698 1,852 1,841 2,253 17 9/30/2024 19,559 1,675 1,695 2,088 N/A 6/30/2024 19,518 1,584 1,617 2,000 N/A 3/31/2024 19,495 1,574 1,663 2,052 N/A 12/31/2023 19,552 1,389 1,714 2,101 N/A 9/30/2023 19,284 1,534 1,723 2,093 N/A 6/30/2023 19,038 1,643 1,701 2,065 N/A 3/31/2023 18,705 1,698 1,760 2,113 N/A 12/31/2022 18,341 1,898 1,803 2,113 N/A 9/30/2022 17,992 1,914 754 1,060 N/A 6/30/2022 17,720 1,929 724 1,016 N/A 3/31/2022 17,582 2,037 1,265 1,555 N/A 12/31/2021 17,585 2,229 1,359 1,607 N/A 12/31/2020 17,164 2,007 1,428 1,687 N/A 12/31/2019 16,633 1,652 1,658 1,989 N/A
Daha fazla göster
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: GEHC 'nin tahmini kazanç büyümesi (yıllık 11.6% ) tasarruf oranının ( 2.6% ) üzerindedir.
Kazançlar ve Piyasa: GEHC şirketinin kazançlarının (yıllık 11.6% ) US pazarından (yıllık 15.6% ) daha yavaş büyümesi öngörülüyor.
Yüksek Büyüme Kazançları: GEHC şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde .
Gelir ve Pazar: GEHC şirketinin gelirinin (yıllık 4.4% ) US pazarından (yıllık 8.9% ) daha yavaş büyümesi öngörülüyor.
Yüksek Büyüme Geliri: GEHC şirketinin gelirinin (yıllık 4.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: GEHC 'nin Özsermaye Getirisi 'nin 3 yıl içinde düşük olması tahmin ediliyor ( 17.4 %).
Büyüyen şirketleri keşfedin Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
